Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Eastern Cooperative Oncology Group
ClinicalTrials.gov Identifier:
NCT00098787
First received: December 8, 2004
Last updated: July 22, 2014
Last verified: July 2014
Results First Received: May 27, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Colorectal Cancer
Interventions: Biological: bevacizumab
Drug: fluorouracil
Drug: irinotecan hydrochloride
Drug: leucovorin calcium
Drug: Oxaliplatin

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
This study was activated on July 14, 2005 and terminated on April 20, 2012, with 247 patients from 25 institutions enrolled to the study.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Only 211 patients were registered to the treatment phase of the study, while the other 36 did not proceed because of ineligibility (n=9), patient withdrawal (n=6), unknown thymidylate synthase (TS)/insufficient sample (n=3), disease progression/decline in TS (n=2), Arm C suspended could not enter Step 2 (n =15), and no insurance (n =1).

Reporting Groups
  Description
Arm A (High TS, IROX/Bev) Patients with high TS who are randomized to Arm A receive irinotecan and oxaliplatin plus bevacizumab (IROX/bev). The combination regimen is administered by giving bevacizumab IV over 30-90 minutes followed by oxaliplatin IV over 2 hours and irinotecan IV over 90 minutes on days 1 and 15 every 28 days until disease progression or until any criterion specified in protocol is met.
Arm B (High TS, FOLFOX/Bev) Patients with high TS who are randomized to Arm B receive 5-Fluorouracil, leucovorin, oxaliplatin, and bevacizumab (FOLFOX/bev). The combination regimen is administered by giving bevacizumab and oxaliplatin as in Arm A, leucovorin calcium IV over 2 hours, and fluorouracil IV over 5 minutes and then continuously over 46 hours on days 1 and 15 every 28 days until disease progression or until any criterion specified in protocol is met.
Arm C (Low or Intermediate TS, FOLFOX/Bev) Patients with low or intermediate TS receive 5-Fluorouracil, leucovorin, oxaliplatin, and bevacizumab (FOLFOX/bev) as in Arm B.

Participant Flow:   Overall Study
    Arm A (High TS, IROX/Bev)     Arm B (High TS, FOLFOX/Bev)     Arm C (Low or Intermediate TS, FOLFOX/Bev)  
STARTED     73     75     63  
Treated     70     73     62  
Eligible and Treated     61     66     59  
COMPLETED     0     0     0  
NOT COMPLETED     73     75     63  
Never started treatment                 3                 2                 1  
Ineligible                 9                 7                 3  
Disease progression                 28                 17                 23  
Adverse Event                 8                 17                 8  
Death                 6                 1                 0  
Withdrawal by Subject                 4                 12                 6  
Alternative therapy                 8                 13                 13  
Unknown                 7                 6                 9  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Eligible and treated patients

Reporting Groups
  Description
Arm A (High TS, IROX/Bev) Patients with high TS who are randomized to Arm A receive irinotecan and oxaliplatin plus bevacizumab (IROX/bev). The combination regimen is administered by giving bevacizumab IV over 30-90 minutes followed by oxaliplatin IV over 2 hours and irinotecan IV over 90 minutes on days 1 and 15 every 28 days until disease progression or until any criterion specified in protocol is met.
Arm B (High TS, FOLFOX/Bev) Patients with high TS who are randomized to Arm B receive 5-Fluorouracil, leucovorin, oxaliplatin, and bevacizumab (FOLFOX/bev). The combination regimen is administered by giving bevacizumab and oxaliplatin as in Arm A, leucovorin calcium IV over 2 hours, and fluorouracil IV over 5 minutes and then continuously over 46 hours on days 1 and 15 every 28 days until disease progression or until any criterion specified in protocol is met.
Arm C (Low or Intermediate TS, FOLFOX/Bev) Patients with low or intermediate TS receive 5-Fluorouracil, leucovorin, oxaliplatin, and bevacizumab (FOLFOX/bev) as in Arm B.
Total Total of all reporting groups

Baseline Measures
    Arm A (High TS, IROX/Bev)     Arm B (High TS, FOLFOX/Bev)     Arm C (Low or Intermediate TS, FOLFOX/Bev)     Total  
Number of Participants  
[units: participants]
  61     66     59     186  
Age  
[units: years]
Median ( Full Range )
  61  
  ( 37 to 85 )  
  60  
  ( 31 to 79 )  
  59  
  ( 29 to 80 )  
  60  
  ( 29 to 85 )  
Gender  
[units: participants]
       
Female     21     30     24     75  
Male     40     36     35     111  
Disease status  
[units: participants]
       
Initial Diagnosis     50     50     50     150  
Recurrence     11     16     9     36  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Objective Response Rate   [ Time Frame: Assessed every 3 months if the patient is within 2 years of registration and every 6 months up to 4 years post-registration. ]

2.  Secondary:   Progression-Free Survival (PFS)   [ Time Frame: Assessed every 3 months if the patient is within 2 years of registration and every 6 months once the patient is 2-4 years post-registration. ]

3.  Secondary:   Overall Survival (OS)   [ Time Frame: Assessed every 3 months if the patient is within 2 years of registration and every 6 months once the patient is 2-4 years post-registration. ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Study Statistician
Organization: Eastern Cooperative Oncology Group (ECOG) Statistical Office
phone: 617-632-3012


No publications provided


Responsible Party: Eastern Cooperative Oncology Group
ClinicalTrials.gov Identifier: NCT00098787     History of Changes
Other Study ID Numbers: CDR0000398096, E4203, U10CA021115
Study First Received: December 8, 2004
Results First Received: May 27, 2014
Last Updated: July 22, 2014
Health Authority: United States: Federal Government